Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 14, 2006. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than general financial performance.
Material Changes
Following a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan (notionally held in GSK Ordinary Share ADRs), an increase in the notional allocation of Ordinary Share ADRs occurred on February 10, 2006. The transaction price was $51.52 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure Rules 3.1.4R (1) (a) and 3.1.4R (1) (b).
Important Facts for Investors
- Transaction Date: February 10, 2006.
- Transaction Price: $51.52 per share for GSK Ordinary Share ADRs.
- Event Type: Increase in notional allocation within the US Retirement Savings Plan.
- Individuals Notified: Dr J P Garnier, Dr W Calhoun, Dr R Greig, Mr D Phelan, Dr D Pulman, Mr D Stout, Mr C Viehbacher, and Dr T Yamada.
- Notification Date: February 13, 2006.